Technical Analysis for APLM - Apollomics Inc.

Grade Last Price % Change Price Change
F 0.12 0.08% 0.00
APLM closed up 0.08 percent on Friday, November 1, 2024, on 44 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness 0.08%
Down 3 Days in a Row Weakness 0.08%
Down 4 Days in a Row Weakness 0.08%
Lower Bollinger Band Touch Weakness 0.08%
Oversold Stochastic Weakness 0.08%
Wide Bands Range Expansion -6.52%
Down 3 Days in a Row Weakness -6.52%

   Recent Intraday Alerts

Alert Time
Down 3% about 23 hours ago
Fell Below Lower Bollinger Band about 23 hours ago
Down 2 % about 23 hours ago
Down 1% about 23 hours ago
Lower Bollinger Band Support about 23 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Apollomics Inc. Description

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Acute Myeloid Leukemia Chemotherapy Non Small Cell Lung Cancer Antineoplastic Drugs Leukemia Targeted Therapy Hematologic Cancers Oncology Therapies Treatment Of Non Small Cell Lung Cancer Phosphoinositide 3 Kinase Inhibitor

Is APLM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.79
52 Week Low 0.1053
Average Volume 916,025
200-Day Moving Average 0.36
50-Day Moving Average 0.13
20-Day Moving Average 0.13
10-Day Moving Average 0.13
Average True Range 0.01
RSI (14) 37.11
ADX 13.35
+DI 17.17
-DI 26.70
Chandelier Exit (Long, 3 ATRs) 0.13
Chandelier Exit (Short, 3 ATRs) 0.15
Upper Bollinger Bands 0.15
Lower Bollinger Band 0.12
Percent B (%b) 0.08
BandWidth 25.23
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram -0.0017
Fundamentals Value
Market Cap 10.65 Million
Num Shares 89.5 Million
EPS -4.34
Price-to-Earnings (P/E) Ratio -0.03
Price-to-Sales 49.74
Price-to-Book 1.15
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.13
Resistance 3 (R3) 0.13 0.13 0.13
Resistance 2 (R2) 0.13 0.13 0.13 0.13
Resistance 1 (R1) 0.12 0.12 0.13 0.12 0.13
Pivot Point 0.12 0.12 0.12 0.12 0.12
Support 1 (S1) 0.11 0.12 0.12 0.11 0.11
Support 2 (S2) 0.11 0.11 0.11 0.11
Support 3 (S3) 0.10 0.11 0.11
Support 4 (S4) 0.10